
Please visit answersincme.com/UZA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Anne Lynn S. Chang, MD and Zeynep Eroglu, MD. In this activity, experts in nonmelanoma skin cancer discuss clinical advances for the use of immunotherapy for the management of basal cell carcinoma (BCC). Upon completion of this activity, participants should be better able to: Evaluate current guideline-based recommendations for the use of immunotherapy in the management of basal cell carcinoma (BCC) across various stages of disease; Apply evidence-driven criteria to identify patients with BCC who may be appropriate candidates for immunotherapeutic intervention; and Determine real-world clinical approaches to optimize the benefit-risk profiles of immunotherapy in the management of BC.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

From Surgery to Systemic Therapy: A Collaborative Discussion on CSCC Neoadjuvant and Adjuvant Immunotherapy

It’s Not "Just Hives": Advancing Targeted Care in Chronic Spontaneous Urticaria

Transforming Outcomes for Patients With Chronic Spontaneous Urticaria: A New Era of Targeted Therapy

From Symptoms to Stability: Emerging OX40/OX40L‐Targeted Therapies, Durable AD Control, and Enhanced Quality of Life
Free AI-powered recaps of CME in Minutes: Education in Dermatology and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.